Covaxin 77.8% effective against covid, says Lancet study

The Lancet study on Covaxin was funded by Bharat Biotech and ICMR.

New Delhi:

Covaxin, the coronavirus vaccine developed by the government’s medical research agency and Bharat Biotech, had found a 77.8 per cent efficacy rate against symptomatic COVID-19 in the long-awaited analysis published in The Lancet. The study found it to be 65.2 percent effective against the more dangerous Delta version of the coronavirus in its preliminary analysis, but said further testing is necessary to confirm this.

Covaxin, which uses conventional, inactivated-virus technology, “produces a strong antibody response” two weeks after the two doses were given, The Lancet said in a statement. The medical journal said no serious-vaccine-related deaths or adverse events were reported in India during a randomized trial involving 24,419 participants aged 18-97 years between November 2020 and May 2021.

“Efficacy against any severity of COVID-19 was 77.8 percent, starting 14 days after the second vaccination … Our preliminary analysis found an efficacy of 65.2 percent against the delta variant, but not clinically against the delta variant. ​Further investigation is necessary to confirm the efficacy. Varis et al,” the study said.

The interim study, which was funded by Bharat Biotech and the Indian Council of Medical Research and partly authored by officials from both bodies, is in line with the company’s earlier efficacy and safety announcements and around the initial authorization of the shot in January may help to resolve disputes. Concerns in India and in some countries.

At the time, the shot was yet to complete its final stages of trials, causing widespread hesitation in the initial weeks of the vaccination campaign. Since then more than 100 million doses of Covaxin have been deployed across India and last week the World Health Organization added the inoculation to its list of authorized COVID vaccines for emergency use.

The decision was delayed as the advisory group sought additional clarification from Bharat Biotech before conducting a final risk-benefit assessment for global use of the vaccine.

The WHO Strategic Advisory Group of Experts on Immunization also recommends the use of Covaxin in two doses, with an interval of four weeks, in age groups 18 years and older. These recommendations are in line with the company’s guidance.

The WHO’s approval and the Lancet study could pave the way for India to supply for the COVAX global vaccine sharing effort, a UN body co-led and aimed at equal access to shots for low- and middle-income countries. to provide access. ,

(with inputs from agencies)

,

Leave a Reply

Your email address will not be published. Required fields are marked *